Education
About Us
Working with TipRanks
Follow Us
Karen Zaderej Insider Profile
4 Followers
Karen Zaderej, CEO, Director at AxoGen, holds 38.50K shares in EyePoint Pharmaceuticals (Ticker: EYPT), holds 1.14M shares in AxoGen (Ticker: AXGN), holds 62.35K shares in Viveve Medical (Ticker: VIVE).
Profitable Transactions
10 out of 11 Profitable Transactions
Average Return
+46.60%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Karen Zaderej holds in companies
Most Profitable Insider Trade
The most profitable trade made by Karen Zaderej
Karen Zaderej's Trading History
AxoGen
Mar 25, 2024
CEO, Director
Uninformative Buy
545.60K
$18.28M
Viveve Medical
Jul 02, 2019
Director
Uninformative Buy
―
―
EyePoint Pharmaceuticals
Jul 11, 2025
Director
Uninformative Buy
22.12K
$539.38K
List of latest transactions for each holding click on a transaction to see Karen Zaderej's performance on stock
You May Also Like
Karen Zaderej insider profile FAQ
What is the percentage of profitable transactions made by Karen Zaderej?
The percentage of profitable transactions made by Karen Zaderej is 91%.
What is the average return per transaction made by Karen Zaderej?
The average return per transaction made by Karen Zaderej is 46.60%.
What stocks does Karen Zaderej hold?
Karen Zaderej holds: AXGN, VIVE, EYPT stocks.
What was Karen Zaderej’s latest transaction?
Karen Zaderej latest transaction was an Uninformative Buy of $22.12K.
What was Karen Zaderej's most profitable transaction?
Karen Zaderej’s most profitable transaction was an Informative Buy of AXGN stock on October 14, 2016. The return on the trade was 122.40%.
What is Karen Zaderej's role in AxoGen?
Karen Zaderej's role in AxoGen is CEO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.